

Anti-ROR1 Antibody (Zilovetamab vedotin)

Introduction

Zilovetamab vedotin (VLS-101, MK-2140) is an Antibody Drug Conjugate (ADC), by targeting ROR1. The drug is composed of a humanized monoclonal antibody and a monomethyl antimitotic cytotoxic agent (MMAE). It has the potential to treat lymphoid malignancies.

Product parameters

Alternative Names	MK-2140, MK 2140, VLS-101
Target Accession	Q01973
Target	ROR1
CAS number	2376463-48-6
Molecular Weight	145.12 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human ROR1 His at 2 ug/mL can bind Anti-ROR1 Reference Antibody (Zilovetamab vedotin), The EC ₅₀ is 0.002833 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

